A Systematic Literature Review of the Humanistic Burden of COPD
- PMID: 34007170
- PMCID: PMC8121160
- DOI: 10.2147/COPD.S296696
A Systematic Literature Review of the Humanistic Burden of COPD
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, causing substantial economic and social burden.
Objective: This review assessed the patient-reported humanistic burden associated with moderate to very severe COPD, specifically the impact on health-related quality of life (HRQoL), symptoms, limitations in daily life, and emotional implications, through the use of HRQoL instruments.
Methods: A systematic review was conducted to retrieve relevant clinical data from published literature using a representative sample of countries where healthcare systems provide wide availability of COPD medications and/or universal coverage includes respiratory medicines (Australia, Canada, China, France, Germany, Italy, Spain, the UK, and the USA). The primary inclusion criteria were patients with moderate to very severe COPD. HRQoL was quantified with non-disease-specific and disease-specific questionnaires.
Results: In total, 82 studies from 95 publications presented HRQoL data from patients with moderate to very severe COPD. Patient-reported HRQoL declined with worsening airflow limitation, advancing GOLD group, and increasing exacerbation frequency. Both increasing frequency of hospitalization for COPD exacerbations and recurrent hospitalization adversely impacted HRQoL. Comorbidity incidence was higher in patients with increased airflow limitation. It was associated with a further decline in HRQoL and increased depression and anxiety, particularly as disease-associated pain worsened. Physical activity improved HRQoL over time.
Conclusion: This review highlighted the impact of exacerbations and associated hospitalizations on the humanistic burden of COPD. These findings underline the importance of managing COPD actively, including prompt and appropriate use of pharmacological and non-pharmacological therapies that can improve symptoms and reduce the risk of exacerbations, thereby lessening the humanistic burden. Future reviews could consider a broader range of countries and publications to further assess the humanistic impact of COPD in low- and middle-income economies.
Keywords: chronic obstructive pulmonary disease; humanistic burden; patient-reported outcomes; quality of life.
© 2021 Hurst et al.
Conflict of interest statement
JRH reports personal payments and payments to UCL for educational and advisory work and support to attend meetings, and grant support to UCL from pharmaceutical companies that make medicines to treat COPD, including AstraZeneca. MKS is an employee of Parexel International. BS is a former employee of Parexel International. PV, UH, and EdN are employees of AstraZeneca and hold stock and/or stock options in the company.
Figures


Similar articles
-
Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2021 Sep 8;9(9):CD013381. doi: 10.1002/14651858.CD013381.pub2. Cochrane Database Syst Rev. 2021. PMID: 34496032 Free PMC article.
-
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD013343. doi: 10.1002/14651858.CD013343.pub2. Cochrane Database Syst Rev. 2022. PMID: 36373977 Free PMC article.
-
Self-management interventions for people with chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4. Cochrane Database Syst Rev. 2022. PMID: 35001366 Free PMC article.
-
Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care.Cochrane Database Syst Rev. 2022 May 6;5(5):CD012652. doi: 10.1002/14651858.CD012652.pub2. Cochrane Database Syst Rev. 2022. PMID: 35514131 Free PMC article.
-
Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review.BMC Res Notes. 2015 Sep 21;8:464. doi: 10.1186/s13104-015-1427-y. BMC Res Notes. 2015. PMID: 26391471 Free PMC article.
Cited by
-
A Systematic Literature Review on the Burden of Disease for Patients With Moderate to Severe Acute Ischemic Stroke.Medicine (Baltimore). 2025 Jan 17;104(3):e41249. doi: 10.1097/MD.0000000000041249. Medicine (Baltimore). 2025. PMID: 39836564 Free PMC article.
-
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.J Manag Care Spec Pharm. 2023 Jul;29(7):791-806. doi: 10.18553/jmcp.2023.22373. Epub 2023 May 3. J Manag Care Spec Pharm. 2023. PMID: 37133429 Free PMC article.
-
Comprehensive comorbidity assessment for the ECOPD: a long-term multi-centre retrospective study.BMC Pulm Med. 2024 Oct 4;24(1):487. doi: 10.1186/s12890-024-03257-6. BMC Pulm Med. 2024. PMID: 39367367 Free PMC article.
-
Prescription is not enough: the importance of adherence to pharmacological treatment of COPD.J Bras Pneumol. 2022 Mar 14;48(1):e20220058. doi: 10.36416/1806-3756/e20220058. J Bras Pneumol. 2022. PMID: 35293494 Free PMC article. No abstract available.
-
Factors associated with health-related quality of life among employed individuals with chronic obstructive pulmonary disease: A correlational study in China.Belitung Nurs J. 2023 Jun 26;9(3):271-279. doi: 10.33546/bnj.2654. eCollection 2023. Belitung Nurs J. 2023. PMID: 37492761 Free PMC article.
References
-
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report. 2021; Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-16.... Accessed February3, 2021. - PubMed
-
- James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. - PMC - PubMed
-
- World Health Organization. Burden of COPD. 2019; Available from: https://www.who.int/respiratory/copd/burden/en/. Accessed November7, 2019.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical